Cargando…
The FDA guidance for industry on PROs: the point of view of a pharmaceutical company
The importance of the patients point of view on their health status is widely recognised. Patient-reported outcomes is a broad term encompassing a large variety of different health data reported by patients, as symptoms, functional status, Quality of Life and Health-Related Quality of Life. Measurem...
Autores principales: | Arpinelli, Fabio, Bamfi, Francesco |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2006
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1636026/ https://www.ncbi.nlm.nih.gov/pubmed/17076891 http://dx.doi.org/10.1186/1477-7525-4-85 |
Ejemplares similares
-
Regulating pharmaceutical companies’ financial largesse
por: Avraham, Ronen, et al.
Publicado: (2018) -
The influence of pharmaceutical companies
por: Migone, Paolo
Publicado: (2017) -
Making pharmaceutical companies report what matters about innovation
por: Cohen, Adam, et al.
Publicado: (2021) -
Cognition comes of age: comments on the new FDA draft guidance for early Alzheimer’s disease
por: Harrison, John E.
Publicado: (2018) -
Factors predicting companies’ crisis in the engineering industry from
the point of view of financial analysis
por: Lukáč, Jozef, et al.
Publicado: (2022)